The Quantellect read.As of Nov 19, 2026, 6 active firms cover Theravance Biopharma Inc: 0 rate it Buy or better, 6 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets span $15.00 to $27.00, a moderate spread. The average target of $19.40 sits 14% above the current $17.03. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $1.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Neutral
Strong Buy00%
Buy00%
Neutral6100%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$19.40
+13.9% upside
Average target across 5 active firms as of Nov 19, 2026 vs $17.03 current
Highest Target$27.00
Average Target$19.40
Lowest Target$15.00
Detailed analyst forecasts for TBPH
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 0 of 6 active firms rate TBPH a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TBPH EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.08 · 1 analysts · -236% YoY
Next period, 1 analysts expect Theravance Biopharma Inc to earn $-0.08 a share (range $-0.08 – $-0.08), versus $0.06 a year earlier. Full-year consensus is $0.21, growing to $1.27 the year after.
REVENUE · NEXT QUARTER
$22.1M
Range $20.7M – $24.1M · 1 analysts · -52% YoY
Revenue is expected to reach $22.1M (range $20.7M – $24.1M), -51.7% year-over-year. Full-year consensus is $89.9M, rising to $84.8M next year.
Top analysts covering Theravance Biopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TBPH.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Neutral
$17.00-0.2% to target
Overall win rate
49%
+ Follow
#2
Julian Harrison
BTIG · Rank #183
Neutral
No targeton TBPH
Overall win rate
41%
+ Follow
#3
Douglas Tsao
HC Wainwright & Co. · Rank #312
Neutral
$17.00-0.2% to target
Overall win rate
35%
+ Follow
#4
TA
Trevor Allred
Oppenheimer
Neutral
$13.67-19.7% to target
Coverage
—
+ Follow
#5
DC
Debanjana Chatterjee
Jones Trading
Neutral
No targeton TBPH
Coverage
—
+ Follow
TBPH stock forecast FAQ
What is TBPH's average 12-month price target?+
The 5 active firms with a live target average $19.40 for Theravance Biopharma Inc over the next 12 months, ranging from a $27.00 high to a $15.00 low, as of Nov 19, 2026.
Is TBPH stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 6 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 6 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TBPH?+
The Street-high target is $27.00, and the Street-low is $15.00 (TD Cowen). The average of all 5 active-firm targets is $19.40.
How many active Wall Street firms cover TBPH?+
6 active firms have a recognized rating on Theravance Biopharma Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TBPH?+
Among analysts who currently cover TBPH, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Neutral with a $17.00 target.
What is Theravance Biopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.08) across 1 analysts. Full-year EPS is projected at $0.21, rising to $1.27 the following year.
How much revenue is Theravance Biopharma Inc expected to report next quarter?+
Consensus revenue is $22.1M (range $20.7M – $24.1M). Full-year revenue is projected at $89.9M, growing to $84.8M next year.
Have analysts been upgrading or downgrading TBPH lately?+
As of Nov 19, 2026, 0 of 6 active firms rate TBPH a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TBPH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.